Hologic (NASDAQ:HOLX) Shares Gap Up - Time to Buy?

Key Points

• Hologic's stock gapped up from $71.87 to $74.63 prior to trading on Tuesday, with a last trading price of $74.31 and a volume of over 7.5 million shares.
• Recent analyst ratings have positive outlooks for Hologic, with targets ranging from $75.00 to $87.00 and a consensus rating of "Moderate Buy."
• Hologic reported an earnings per share (EPS) of $1.08 for the last quarter, beating expectations of $1.05 and showing a revenue increase of 1.2% year-over-year.

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $71.87, but opened at $74.63. Hologic shares last traded at $74.31, with a volume of 7,590,888 shares trading hands.

Analyst Ratings Changes

A number of brokerages recently commented on HOLX. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Stephens restated an "overweight" rating and set a $78.00 target price on shares of Hologic in a report on Thursday, September 18th. Morgan Stanley boosted their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $80.15.

Hologic Stock Up 3.3%

The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The firm's fifty day simple moving average is $67.19 and its 200 day simple moving average is $63.62. The stock has a market capitalization of $16.51 billion, a price-to-earnings ratio of 30.79, a P/E/G ratio of 2.40 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm earned $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.88% of the company's stock.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its stake in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider's stock valued at $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider's stock valued at $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Norges Bank acquired a new stake in shares of Hologic in the second quarter valued at approximately $180,055,000. Victory Capital Management Inc. lifted its position in shares of Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Hologic by 473.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider's stock worth $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.